Article
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.
Nature communications - 19 Dec 2017
Landau Dan A, Sun Clare, Rosebrock Daniel, Herman Sarah E M, Fein Joshua, Sivina Mariela, Underbayev Chingiz, Liu Delong, Hoellenriegel Julia, Ravichandran Sarangan, Farooqui Mohammed Z H, Zhang Wandi, Cibulskis Carrie, Zviran Asaf, Neuberg Donna S, Livitz Dimitri, Bozic Ivana, Leshchiner Ignaty, Getz Gad, Burger Jan A, Wiestner Adrian, Wu Catherine J
Abstract excerpt
Treatment of chronic lymphocytic leukemia (CLL) has shifted from chemo-immunotherapy to targeted agents. To define the evolutionary dynamics induced by targeted therapy in CLL, we perform serial exome and transcriptome sequencing for 61 ibrutinib-treated CLLs. Here, we report clonal shifts (change >0.1 in clonal cancer cell fraction, Q < 0.1) in 31% of patients during the first year of therapy, associated with...
Topics
Join the communities discussing this publication.